– USA, NC – Evecxia Therapeutics, Inc., a biopharmaceutical company focused on treating patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate, today announced that Thomas Aasen has joined its Board of Directors.
Mr. Aasen is a financial executive with over thirty years of professional experience, including financial management positions in four publicly held life science companies.
“Tom brings extensive financial experience and leadership to our Board,” said John Kaiser, CEO, President and Chairman.
He added: “Over the course of his career, Tom has successfully proven his financial expertise. Tom was an integral member of the executive team that advanced ACADIA from an early-stage private company into a multi-billion dollar publicly held biopharmaceutical company. He played a lead role in overseeing ACADIA’s IPO and closing several private and public financings raising over $700 million. Tom brings decades of knowledge and expertise making him a natural fit at Evecxia as we advance our pipeline targeting disabling neuropsychiatric conditions.”
About Tom Aasen
Mr. Aasen served as the EVP, CFO, Chief Business Officer, and Treasurer of ACADIA before his retirement in 2014. Mr. Aasen has held financial management positions at several publicly traded life sciences companies, including Axys Pharmaceuticals, formerly called Sequana Therapeutics, Genta, Inc., and Gen-Probe, Inc. Earlier in his career, Mr. Aasen held various positions in public accounting at KPMG Peat Marwick, including Audit Manager. He has 30 years of professional finance and accounting experience focused primarily on the life sciences industry.
Mr. Aasen received a B.S. degree with honors from San Diego State University and is a licensed certified public accountant in the State of California.
About Evecxia Therapeutics, Inc.
Evecxia Therapeutics is a privately funded, clinical-stage pharmaceutical company, located in Research Triangle Park, NC. Evecxia’s mission is to help treat patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate and sub-optimal.
Evecxia is the first company dedicated to realizing the therapeutic potential of 5-hydroxytryptophan via specialized prescription combinations and drug delivery dosage forms. Evecxia has licensed a comprehensive portfolio of issued and pending patents on the 5-HTP slow-release method and related technologies from Duke University and Duke-National University Singapore.
For more information: https://evecxia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
